PRotective Effect on the coronary microcirculation of patients with DIabetes by Clopidogrel or Ticagrelor (PREDICT): study rationale and design. A randomized multicenter clinical trial using intracoronary multimodal physiology

Cardiovascular Diabetology
Enrico CerratoJavier Escaned

Abstract

In diabetic patients a predisposed coronary microcirculation along with a higher risk of distal particulate embolization during primary percutaneous intervention (PCI) increases the risk of peri-procedural microcirculatory damage. However, new antiplatelet agents, in particular Ticagrelor, may protect the microcirculation through its adenosine-mediated vasodilatory effects. PREDICT is an original, prospective, randomized, multicenter controlled study designed to investigate the protective effect of Ticagrelor on the microcirculation during PCI in patient with diabetes mellitus type 2 or pre-diabetic status. The primary endpoints of this study aim to test (i) the decrease in microcirculatory resistance with antiplatelet therapy (Ticagrelor > Clopidogrel; mechanistic effect) and (ii) the relative microcirculatory protection of Ticagrelor compared to Clopidogrel during PCI (Ticagrelor < Clopidogrel; protective effect). PREDICT will be the first multicentre clinical trial to test the adenosine-mediated vasodilatory effect of Ticagrelor on the microcirculation during PCI in diabetic patients. The results will provide important insights into the prospective beneficial effect of this drug in preventing microvascular impairment related...Continue Reading

References

Dec 1, 1990·Metabolism: Clinical and Experimental·A GreenD J DiPette
Dec 1, 2001·Pharmacology & Therapeutics·R Tabrizchi, S Bedi
Jun 25, 2003·Circulation·William F FearonAlan C Yeung
Apr 20, 2004·Journal of the American College of Cardiology·Roxana MehranMartin B Leon
Aug 9, 2005·American Heart Journal·Ugo LimbrunoRaffaele De Caterina
Aug 7, 2007·Journal of the American College of Cardiology·Jacques MachecourtUNKNOWN EVASTENT Investigators
Feb 24, 2009·Journal of the American College of Cardiology·Michael V Cohen, James M Downey
Jul 30, 2009·Handbook of Experimental Pharmacology·John P Headrick, Robert D Lasley
Jun 24, 2011·Journal of Cardiovascular Pharmacology and Therapeutics·J J J van GiezenJan-Arne Björkman
Oct 11, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Andrea PicchiRaffaele De Caterina
Aug 28, 2012·Circulation·Kristian ThygesenShanti Mendis
Jan 15, 2013·Journal of the American College of Cardiology·Ann WittfeldtLi-Ming Gan
Jun 15, 2013·Pharmacology & Therapeutics·John P HeadrickJason N Peart
Dec 21, 2013·Diabetes Care·UNKNOWN American Diabetes Association
Feb 18, 2014·Heart, Lung & Circulation·Scott R WilloughbyMatthew I Worthley
Apr 29, 2014·Journal of the American College of Cardiology·Marco CattaneoSven Nylander
Aug 12, 2014·Journal of Cardiovascular Medicine·Claudio MorettiFiorenzo Gaita
May 31, 2015·Cardiovascular Diabetology·Dimitrios AlexopoulosIoanna Xanthopoulou
Jul 9, 2016·Journal of the American College of Cardiology·Fabio MangiacapraEmanuele Barbato

❮ Previous
Next ❯

Methods Mentioned

BETA
infrared spectroscopy

Clinical Trials Mentioned

NCT02698618

Software Mentioned

R
PREDICT

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.